Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79702.690.1727%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Metagenomi Therapeutics Inc

MGXNASDAQ
Trade with Public
Trade with Public
$1.17
0.010.86%
At close: Sep 4, 5:00 PM EST
$1.17
N/A
After Hours: Sep 4, 9:25 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Metagenomi Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Metagenomi Therapeutics (MGX).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+787.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Wells FargoYanan ZhuPT CutOverweight$9→$7
Jul 7, 2026Chardan CapitalKeay NakaePT CutBuy$7→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $16 to $12.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved